Regulatory strategy as commercial advantage in health tech
Ask most health technology founders when they will deal with regulation and the answer is some version of “once the product is ready”. That framing treats regulation as a gate at the end of a corridor. It is more useful to treat it as a set of commercial choices made at the beginning, because regulatory decisions determine what you can sell, to whom, in which country, at what price, and how quickly.
Four commercial decisions disguised as regulatory ones
1. What you are allowed to claim
Your intended purpose is a regulatory statement, but it is also your marketing boundary. A product described as supporting clinician decisions is a different commercial proposition from one described as detecting a condition, and the difference shows up in the class of the device, the evidence required, the price a buyer will accept and the sales process needed to close.
Companies that write the intended purpose late usually write it defensively, to minimise regulatory burden. That is a reasonable instinct, but it is a pricing decision taken by the wrong people at the wrong time.
2. Which market you enter first
The UK and EU are no longer a single decision. In Great Britain, UKCA marking applies under the UK MDR 2002, while CE-marked devices may still be placed on the GB market until 30 June 2028 or 30 June 2030 depending on device type, and the MHRA has consulted on recognising EU MDR and IVDR devices indefinitely (MHRA; Inside EU Life Sciences, 2026).
The MHRA’s draft Medical Devices (Amendment) Regulations 2026 would also introduce an international reliance pathway allowing devices approved in certain other jurisdictions to reach the GB market more quickly (MedDeviceGuide, 2026). Meanwhile EU notified body capacity continues to produce long review timelines for higher-risk devices (ElendiLabs, 2026).
Sequencing therefore has real commercial consequences. A company that certifies in the EU first may reach a larger market but wait longer. A company that starts in GB may move faster but must plan its EU route before the transitional arrangements close. Neither is universally right. Choosing without analysing is what costs money.
3. How fast you can improve the product
Software teams ship continuously. Medical device frameworks were built around products that change rarely. The gap between the two is where health tech companies lose velocity.
The MHRA’s draft 2026 regulations formalise predetermined change control plans for software and AI-enabled devices, allowing manufacturers to define anticipated modifications in advance rather than seeking assessment each time (Patient Guard, 2026). The MHRA has also run its AI Airlock regulatory sandbox for AI-enabled devices. Designing your release process around these mechanisms is a product velocity decision, and velocity is competitive advantage.
4. Whether AI is an asset or an unpriced liability
If your device requires a notified body under the EU MDR or IVDR and contains AI, it is a high-risk AI system under the EU AI Act, and the AI Act requirements are assessed through the conformity route you already use rather than a separate process (mdxCRO, 2026). The Digital Omnibus, Regulation (EU) 2026/1744, in force since 27 July 2026, moved the deadline for AI embedded in regulated products to 2 August 2028, with standalone high-risk systems at 2 December 2027 (White & Case, 2026).
The practical point for a commercial team is that data governance, logging, human oversight and bias evaluation now sit on the critical path to revenue in Europe. Buyers and notified bodies are already asking these questions ahead of the legal deadlines. In the UK, the MHRA has committed to a dedicated framework for AI as a medical device (RegDesk, 2026).
Where regulation meets the buyer
In England, regulatory status feeds directly into the sales process. The updated Digital Technology Assessment Criteria includes a decision tree for determining whether a product is a medical device and which clinical safety standard applies, and software that qualifies as a medical device triggers further procurement checks (Burges Salmon, 2026). NICE’s Evidence Standards Framework sets out what evidence is expected of digital health technologies, and refers to DTAC, DCB0129 and DCB0160 (NICE).
An unclear regulatory position is therefore not a private problem. It surfaces in front of the customer, at the point of maximum commercial damage.
Using regulation deliberately
- Treat classification as a pricing and positioning exercise, and model more than one option.
- Sequence markets against your funding runway, not your ambition.
- Build the evidence package once, and reuse it across regulatory submissions, NHS assurance, NICE evidence expectations and investor diligence.
- Make your release process compatible with your regulatory route, so improvement does not require permission every time.
- Keep a current regulatory narrative for investors and acquirers. Diligence rewards clarity and punishes ambiguity.
Done well, regulatory strategy narrows your competitive field. Most competitors will avoid the work, and the barrier that slowed you becomes the barrier protecting you.
How FastForward can help
- Regulatory and commercial alignment. We connect classification, claims, pricing and market sequencing into one plan your board can act on.
- Market entry sequencing. UK, EU and beyond, mapped against capacity, cost and runway.
- AI readiness. Practical preparation for AI Act obligations alongside MDR or UK requirements, without duplicating work.
- Evidence strategy. One evidence package serving regulators, NHS assurance, NICE expectations and investors.
To talk it through, email hello@fwdtech.co.uk.
References
1. MHRA, Regulating medical devices in the UK, GOV.UK — https://www.gov.uk/guidance/regulating-medical-devices-in-the-uk
2. Inside EU Life Sciences (2026), MHRA consultation on indefinite recognition of the CE mark — https://www.insideeulifesciences.com/2026/02/17/uk-mhra-announces-consultation-on-the-indefinite-recognition-of-ce-marked-medical-devices/
3. MedDeviceGuide (2026), UK MHRA International Reliance Pathway — https://meddeviceguide.com/blog/uk-mhra-international-reliance-pathway-draft-regulation-2026-guide
4. Patient Guard (2026), The MHRA 2026 regulatory roadmap explained — https://patientguard.com/the-mhra-2026-regulatory-roadmap-explained/
5. mdxCRO (2026), EU AI Act for medical devices and SaMD — https://mdxcro.com/eu-ai-act-medical-devices-samd/
6. White & Case (2026), EU AI Omnibus enters into force — https://www.whitecase.com/insight-alert/eu-ai-omnibus-enters-force-amending-ai-act
7. RegDesk (2026), MHRA guidance on software and AI as a medical device — https://www.regdesk.co/blog/mhra-guidance-on-software-and-ai-as-a-medical-device/
8. NICE, Evidence standards framework for digital health technologies — https://www.nice.org.uk/corporate/ecd7/resources/evidence-standards-framework-for-digital-health-technologies-pdf-1124017457605
9. Burges Salmon (2026), New NHS Digital Technology Assessment Criteria — https://www.burges-salmon.com/articles/102mnjh/new-nhs-digital-technology-assessment-criteria-what-health-tech-suppliers-need-t/